Biotech - Spark Newswire

1 minute read

EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm

Today, 9:01 AM

BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for the expanded clinical application of BRTX-100.

BRTX

1 minute read

Sanofi Has Agreed To Acquire Provention Bio For $25.00/Share In Cash, Representing An Equity Value Of Approximately $2.9B

By Benzinga Newsdesk

Today, 9:01 AM

https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367

PRVB

2 minute read

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs

By Vandana Singh

Today, 9:01 AM

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.

AMGN

2 minute read

FDA Addresses ‘Misinformation’ Concerning Delayed Approval Of Lucira Health’s COVID-19 & Flu Home Test

By Vandana Singh

Today, 9:01 AM

The FDA provided additional information about the agency’s interactions and decisions regarding the emergency use authorization (EUA) of Lucira Health Inc’s (OTC: LHDXQ)…

LHDX

1 minute read

FDA Seeks 10% Increase In Biden’s FY 2024 Budget, Proposes Enhancing Regulatory Authorities

By Vandana Singh

Today, 9:01 AM

The FDA has requested $7.2 billion as part of the president’s fiscal year 2024 budget, $128.2 million of which the…

ABT

1 minute read

Annji Pharmaceutical Has Entered Into An Exclusive License Agreement With Avenue Therapeutics For AJ201 For Spinal And Bulbar Muscular Atrophy, Also Known As Kennedy’s Disease; Upfront Payment Of $3M, Milestone Payments Of Upto $250M

By Benzinga Newsdesk

Today, 9:01 AM

The deal covers the U.S., Canada, European Union, Great Britain, And Israel. Avenue will also issue 831,618 shares as equity upfront and additional shares upon the achievement of a clinical milestone, aggregating

ATXI

1 minute read

Reported Late Thursday March 9, MediciNova Announces Additional Extension Of BARDA Contract To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-induced Lung Injury; Contract Was Amended To Extend The Period Of Performance Until May 31, 2…

By Happy Mohamed

Today, 9:01 AM

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with

MNOV

2 minute read

Bill Gates Is Not Expecting You To Give Up Meat, Even Though The Planet Could Benefit From It — Here’s Why

By Natan Ponieman

Today, 9:01 AM

In a lecture given last week at the fifth Ramnath Goenka Lecture in India, former Microsoft CEO and…

BYND

1 minute read

FDA Casts Doubts Over Roche’s Polivy Label Expansion For Untreated Lymphoma Setting

By Vandana Singh

Today, 9:01 AM

Today, the FDA Oncologic Drugs Advisory Committee is discussing the supplemental marketing application for Polivy (polatuzumab vedotin-piiq) plus Rituxan (rituximab)…

RHHBF

1 minute read

William Blair Initiates Mesoblast Soon After Its Lead Product Goes Under FDA Review In Pediatric Indication

By Vandana Singh

Today, 9:01 AM

William Blair has initiated coverage on Mesoblast Ltd (NASDAQ:MESO) with an Outperform rating and a price target of $8. Mesoblast’s lead product,…

MESO